NCT04475640
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 4
Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must self-identify as being from various ethnic populations including Hispanic/Latino, Native American/Alaskan, African American (including of African descent, Asian, and other European populations)
Exclusions: 
https://ClinicalTrials.gov/show/NCT04475640